Clinical trials: Papulopustular Rosacea
Papulopustular Rosacea
Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer…
- Trial name
- NCT03079531
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Anne Chang
Papulopustular Rosacea
CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Study objectives: To compare efficacy and safety of Ivermectin 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea after 16-week topical treatment.
- Trial name
- ATTRACT (NCT01493947)
- Testing
- Ivermectin 1% cream, Metronidazole 0.75% cream
- Where
- 60 sites in Bulgaria, Czechia and 8 more
- Volunteers
- 962 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
This exploratory study is being performed to determine whether a new form formulation of azelaic acid 15% is effective in the treatment of papulopustular rosecea.
- Trial name
- NCT00617903
- Testing
- Azelaic acid, Vehicle foam
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03564119
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Open Label Pilot Study of Apremilast in Treatment of Rosacea
Rosacea is a chronic skin disorder with the signs and symptoms of facial flushing, persistent redness, small visible spider-like veins, papules (inflamed red bumps under the skin) and pustules.
- Trial name
- NCT01045551
- Testing
- Apremilast
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Julian M. Mackay-Wiggan
Facial Papulopustular Rosacea
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT04608500
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 46 sites in United States
- Volunteers
- 771 people
- Sponsor
- Vyne Therapeutics Inc.
Rosacea
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.
- Trial name
- NCT02576860
- Testing
- CLS001 (Omiganan), Vehicle
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Rosacea
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular…
- Trial name
- NCT01308619
- Testing
- Doxycycline
- Where
- 10 sites in United States
- Volunteers
- 170 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.
- Trial name
- NCT03276936
- Testing
- FMX103 1.5%
- Where
- 79 sites in United States
- Volunteers
- 504 people
- Sponsor
- Vyne Therapeutics Inc.
Papulopustular Rosacea
An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
This study is designed to investigate whether topical application of a cromolyn sodium solution is able to decrease the facial redness seen in patients with papulopustular rosacea. Previous work in the lab of Dr.
- Trial name
- NCT01933464
- Testing
- Cromolyn Sodium, Normal Saline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego